Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib
Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/6185943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214515213336576 |
|---|---|
| author | Michael J. Forte Rahul G. Sangani |
| author_facet | Michael J. Forte Rahul G. Sangani |
| author_sort | Michael J. Forte |
| collection | DOAJ |
| description | Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically within the first few months after initiation. Previously reported pulmonary adverse reactions include pneumonitis (nonspecific interstitial pneumonia or other forms of acute interstitial process), fleeting asymptomatic infiltrates on imaging, and eosinophilic pneumonia. We present an interesting case of a 65-year-old female with recurrent metastatic adenocarcinoma of the lung, treated with Osimertinib for 4 months, who developed a previously unreported toxicity of diffuse alveolar hemorrhage (DAH) requiring mechanical ventilatory support. |
| format | Article |
| id | doaj-art-813edb2b8b1340beb6f9dbaffc4908e2 |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-813edb2b8b1340beb6f9dbaffc4908e22025-08-20T02:08:53ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/61859436185943Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from OsimertinibMichael J. Forte0Rahul G. Sangani1West Virginia University, Department of Pulmonary and Critical Care Medicine, PO BOX 9166 1 Medical Center Drive, Morgantown, WV 26506, USAWest Virginia University, Department of Pulmonary and Critical Care Medicine, PO BOX 9166 1 Medical Center Drive, Morgantown, WV 26506, USAOsimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically within the first few months after initiation. Previously reported pulmonary adverse reactions include pneumonitis (nonspecific interstitial pneumonia or other forms of acute interstitial process), fleeting asymptomatic infiltrates on imaging, and eosinophilic pneumonia. We present an interesting case of a 65-year-old female with recurrent metastatic adenocarcinoma of the lung, treated with Osimertinib for 4 months, who developed a previously unreported toxicity of diffuse alveolar hemorrhage (DAH) requiring mechanical ventilatory support.http://dx.doi.org/10.1155/2019/6185943 |
| spellingShingle | Michael J. Forte Rahul G. Sangani Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib Case Reports in Oncological Medicine |
| title | Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib |
| title_full | Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib |
| title_fullStr | Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib |
| title_full_unstemmed | Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib |
| title_short | Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib |
| title_sort | emerging risk profile of lung cancer therapy diffuse alveolar hemorrhage from osimertinib |
| url | http://dx.doi.org/10.1155/2019/6185943 |
| work_keys_str_mv | AT michaeljforte emergingriskprofileoflungcancertherapydiffusealveolarhemorrhagefromosimertinib AT rahulgsangani emergingriskprofileoflungcancertherapydiffusealveolarhemorrhagefromosimertinib |